BioLineRx (BLRX) Competitors $0.20 +0.00 (+0.50%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends BLRX vs. DBVT, BCAB, VHAQ, SLS, INCR, CUE, ONCY, BYSI, VNRX, and ATRAShould you be buying BioLineRx stock or one of its competitors? The main competitors of BioLineRx include DBV Technologies (DBVT), BioAtla (BCAB), Viveon Health Acquisition (VHAQ), SELLAS Life Sciences Group (SLS), InterCure (INCR), Cue Biopharma (CUE), Oncolytics Biotech (ONCY), BeyondSpring (BYSI), VolitionRx (VNRX), and Atara Biotherapeutics (ATRA). These companies are all part of the "pharmaceutical products" industry. BioLineRx vs. DBV Technologies BioAtla Viveon Health Acquisition SELLAS Life Sciences Group InterCure Cue Biopharma Oncolytics Biotech BeyondSpring VolitionRx Atara Biotherapeutics BioLineRx (NASDAQ:BLRX) and DBV Technologies (NASDAQ:DBVT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, profitability, dividends, analyst recommendations, institutional ownership, valuation, risk, earnings and media sentiment. Do analysts recommend BLRX or DBVT? BioLineRx presently has a consensus price target of $9.00, suggesting a potential upside of 4,333.50%. DBV Technologies has a consensus price target of $22.50, suggesting a potential upside of 605.33%. Given BioLineRx's higher probable upside, equities research analysts plainly believe BioLineRx is more favorable than DBV Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioLineRx 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00DBV Technologies 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals and insiders believe in BLRX or DBVT? 1.6% of BioLineRx shares are held by institutional investors. Comparatively, 71.7% of DBV Technologies shares are held by institutional investors. 1.1% of BioLineRx shares are held by company insiders. Comparatively, 1.9% of DBV Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the MarketBeat Community favor BLRX or DBVT? BioLineRx received 102 more outperform votes than DBV Technologies when rated by MarketBeat users. Likewise, 72.39% of users gave BioLineRx an outperform vote while only 55.27% of users gave DBV Technologies an outperform vote. CompanyUnderperformOutperformBioLineRxOutperform Votes50672.39% Underperform Votes19327.61% DBV TechnologiesOutperform Votes40455.27% Underperform Votes32744.73% Which has more volatility & risk, BLRX or DBVT? BioLineRx has a beta of 1.39, indicating that its stock price is 39% more volatile than the S&P 500. Comparatively, DBV Technologies has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500. Which has higher valuation and earnings, BLRX or DBVT? BioLineRx has higher revenue and earnings than DBV Technologies. BioLineRx is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioLineRx$21.99M0.74-$60.61M-$0.22-0.92DBV Technologies$15.73M4.17-$72.73M-$4.50-0.71 Is BLRX or DBVT more profitable? BioLineRx has a net margin of -90.57% compared to DBV Technologies' net margin of -815.73%. DBV Technologies' return on equity of -106.07% beat BioLineRx's return on equity.Company Net Margins Return on Equity Return on Assets BioLineRx-90.57% -163.37% -34.21% DBV Technologies -815.73%-106.07%-76.17% Does the media refer more to BLRX or DBVT? In the previous week, DBV Technologies had 3 more articles in the media than BioLineRx. MarketBeat recorded 3 mentions for DBV Technologies and 0 mentions for BioLineRx. DBV Technologies' average media sentiment score of 0.20 beat BioLineRx's score of 0.00 indicating that DBV Technologies is being referred to more favorably in the news media. Company Overall Sentiment BioLineRx Neutral DBV Technologies Neutral SummaryBioLineRx beats DBV Technologies on 9 of the 17 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Get BioLineRx News Delivered to You Automatically Sign up to receive the latest news and ratings for BLRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BLRX vs. The Competition Export to ExcelMetricBioLineRxPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.23M$6.57B$5.12B$9.07BDividend YieldN/A2.98%4.91%4.22%P/E Ratio-0.9210.5991.3417.19Price / Sales0.74195.381,116.63116.80Price / CashN/A57.1642.5837.86Price / Book1.135.104.794.78Net Income-$60.61M$151.51M$120.07M$225.60M7 Day Performance-9.74%-2.14%-1.90%-1.24%1 Month Performance-37.21%-3.13%11.43%3.06%1 Year Performance-87.77%11.51%30.59%16.50% BioLineRx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BLRXBioLineRx2.1571 of 5 stars$0.20+0.5%$9.00+4,333.5%-87.2%$16.23M$21.99M-0.9240Analyst ForecastDBVTDBV Technologies3.5378 of 5 stars$3.25-9.0%$22.50+592.3%-66.8%$66.85M$15.73M-0.73106Gap DownBCABBioAtla2.4616 of 5 stars$1.38-5.1%$6.00+336.0%-65.7%$66.54M$11M-0.8560News CoverageGap DownVHAQViveon Health AcquisitionN/A$10.00flatN/AN/A$66.49MN/A0.002SLSSELLAS Life Sciences Group0.0096 of 5 stars$0.94+8.3%N/A-27.2%$66.47M$1M-1.3916INCRInterCure0.1035 of 5 stars$1.42+7.8%N/A+16.4%$64.71M$272.67M0.00350News CoverageGap UpCUECue Biopharma4.687 of 5 stars$1.02+8.5%$5.00+390.2%-63.1%$64.62M$9.53M-1.0360News CoveragePositive NewsGap UpONCYOncolytics Biotech1.9125 of 5 stars$0.83+1.4%$4.00+384.8%-33.0%$63.58MN/A0.0030News CoverageBYSIBeyondSpringN/A$1.60-2.7%N/A+72.8%$62.25M$1.88M0.0080Positive NewsGap DownVNRXVolitionRx1.7538 of 5 stars$0.67+18.6%$3.75+459.7%+2.4%$62.09M$770,000.00-1.5780Gap UpATRAAtara Biotherapeutics3.8375 of 5 stars$10.59+2.5%$16.67+57.4%-17.6%$61.00M$100.44M-0.40165Analyst ForecastNews CoverageGap Up Related Companies and Tools Related Companies DBVT Competitors BCAB Competitors VHAQ Competitors SLS Competitors INCR Competitors CUE Competitors ONCY Competitors BYSI Competitors VNRX Competitors ATRA Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BLRX) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioLineRx Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioLineRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BLRX Stock Alerts